{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:11:24Z","timestamp":1789031484118,"version":"build-2803163510"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      Genetic variation has been proposed as a potential contributor to antidepressant nonresponse, but its role in treatment-resistant depression (TRD) remains unclear. This study used pharmacogenetics (PGx) to characterize genetic variation in TRD and determine whether actionable PGx variation and drug\n                      <jats:bold>\u2013<\/jats:bold>\n                      gene interaction (DGI) mismatch were associated with antidepressant nonresponse and TRD burden.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This observational study included 158 individuals with TRD recruited from outpatient clinics in Western Australia. Genotype and genotype-predicted phenotypes for\n                      <jats:italic toggle=\"yes\">CYP2B6<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">CYP2C19<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">CYP2D6<\/jats:italic>\n                      were derived from commercial PGx testing and compared with ethnicity-matched reference populations from ClinPGx. Antidepressant-specific DGIs were classified as actionable or nonactionable according to Clinical Pharmacogenetics Implementation Consortium guidelines, and unsupervised clustering was used to identify clusters based on these actionability profiles. Analyses were performed to determine if actionable PGx variation, cluster membership, or PGx mismatch was associated with TRD burden (number of failed antidepressant trials).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PGx variation in the TRD cohort was consistent with population expectations, with no evidence of enrichment for actionable PGx variants. Clustering identified six clusters with distinct and gene-specific patterns of PGx variation independent of demographic and clinical characteristics. However, neither PGx mismatch nor cluster membership were associated with TRD burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that actionable PGx phenotypes are neither enriched in TRD nor associated with greater TRD severity. Rather, the results indicate that TRD does not represent a single, unified PGx-predicted \u2018poor pharmacological responder\u2019 phenotype but instead reflects a biologically heterogeneous collection of distinct PGx profiles.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000621","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:00:06Z","timestamp":1789030806000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Beyond enrichment: pharmacogenetic heterogeneity in treatment-resistant depression"],"prefix":"10.1097","author":[{"given":"Bradley","family":"Roberts","sequence":"first","affiliation":[{"name":"Perron Institute for Neurological and Translational Science, Nedlands"},{"name":"School of Biological Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Miljevic","sequence":"additional","affiliation":[{"name":"Perron Institute for Neurological and Translational Science, Nedlands"},{"name":"School of Biomedical Sciences, The University of Western Australia, Crawley"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A","family":"Hennessy","sequence":"additional","affiliation":[{"name":"Modalis TMS, Stirling"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlan A","family":"Boax","sequence":"additional","affiliation":[{"name":"Modalis TMS, Stirling"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Hoath","sequence":"additional","affiliation":[{"name":"Modalis TMS, Stirling"},{"name":"School of Medicine, The University of Notre Dame, Fremantle, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Bousman","sequence":"additional","affiliation":[{"name":"Alberta Children\u2019s Hospital Research Institute, University of Calgary"},{"name":"Department of Medical Genetics"},{"name":"The Mathison Centre for Mental Health Research & Education, Hotchkiss Brain Institute, Cumming School of Medicine"},{"name":"Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D","family":"Hood","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, School of Medicine, The University of Western Australia, Crawley"},{"name":"North Metropolitan Health Service, Western Australian Department of Health, Perth"},{"name":"Suicide Prevention and Resilience Research Centre, School of Psychological Science, The University of Western Australia, Crawley, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Rodger","sequence":"additional","affiliation":[{"name":"Perron Institute for Neurological and Translational Science, Nedlands"},{"name":"School of Biological Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"R1-20260910","doi-asserted-by":"crossref","first-page":"435","DOI":"10.31887\/DCNS.2009.11.4\/afleuchter","article-title":"A new paradigm for the prediction of antidepressant treatment response.","volume":"11","author":"Leuchter","year":"2009","journal-title":"Dialogues Clin Neurosci"},{"key":"R2-20260910","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0004867420979353","article-title":"The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.","volume":"55","author":"Malhi","year":"2021","journal-title":"Aust N Z J Psychiatry"},{"key":"R3-20260910","first-page":"76","article-title":"Switching and stopping antidepressants.","volume":"39","author":"Keks","year":"2016","journal-title":"Aust Prescr"},{"key":"R4-20260910","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R5-20260910","doi-asserted-by":"crossref","first-page":"e063095","DOI":"10.1136\/bmjopen-2022-063095","article-title":"What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study\u2019s patient-level data with fidelity to the original research protocol.","volume":"13","author":"Pigott","year":"2023","journal-title":"BMJ Open"},{"key":"R6-20260910","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/PPA.S29716","article-title":"Treatment-resistant depression: therapeutic trends, challenges, and future directions.","volume":"6","author":"Al-Harbi","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"R7-20260910","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12888-019-2222-4","article-title":"The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study.","volume":"19","author":"Jaffe","year":"2019","journal-title":"BMC Psychiatry"},{"key":"R8-20260910","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"R9-20260910","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3390\/ph18091360","article-title":"Pharmacogenetics and the response to antidepressants in major depressive disorder.","volume":"18","author":"Bertollo","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"R10-20260910","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/s41380-025-03357-7","article-title":"Genome-wide meta-analyses of non-response to antidepressants provide insights into underlying molecular genetics and suggest potential pharmacotherapies.","volume":"31","author":"Koch","year":"2026","journal-title":"Mol Psychiatry"},{"key":"R12-20260910","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.biopsych.2012.10.030","article-title":"Contribution of common genetic variants to antidepressant response.","volume":"73","author":"Tansey","year":"2013","journal-title":"Biol Psychiatry"},{"key":"R13-20260910","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/a-1288-1061","article-title":"Review and consensus on pharmacogenomic testing in psychiatry.","volume":"54","author":"Bousman","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"R14-20260910","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41397-019-0122-0","article-title":"Drug-drug-gene interactions and adverse drug reactions.","volume":"20","author":"Malki","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"R15-20260910","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jpsychires.2019.01.003","article-title":"Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study.","volume":"111","author":"Greden","year":"2019","journal-title":"J Psychiatr Res"},{"key":"R16-20260910","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1089\/cap.2023.0043","article-title":"High probability of gene-drug interactions associated with medication side effects in adolescent depression: results from a randomized controlled trial of pharmacogenetic testing.","volume":"34","author":"Nooraeen","year":"2024","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R17-20260910","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.62641\/aep.v53i6.1946","article-title":"Rethinking treatment-resistant depression: a systematic review of novel therapeutic strategies and precision medicine approaches.","volume":"53","author":"Tatli","year":"2025","journal-title":"Actas Esp Psiquiatr"},{"key":"R18-20260910","doi-asserted-by":"crossref","first-page":"00185787251396791","DOI":"10.1177\/00185787251396791","article-title":"Treatment-resistant depression: esketamine is promising, but personalized medicine including pharmacogenetic testing should come first.","volume":"0","author":"Belan\u010di\u0107","year":"2025","journal-title":"Hosp Pharm"},{"key":"R19-20260910","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41380-021-01200-3","article-title":"Treatment resistance in psychiatry: state of the art and new directions.","volume":"27","author":"Howes","year":"2022","journal-title":"Mol Psychiatry"},{"key":"R20-20260910","doi-asserted-by":"crossref","first-page":"566","DOI":"10.37765\/ajmc.2022.89259","article-title":"Predicting drug-drug and drug-gene interactions in a community pharmacy population.","volume":"28","author":"Dowd","year":"2022","journal-title":"Am J Manag Care"},{"key":"R22-20260910","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cpt.2903","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants.","volume":"114","author":"Bousman","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"R23-20260910","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.597","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R24-20260910","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12888-018-1679-x","article-title":"Standardisation framework for the Maudsley staging method for treatment resistance in depression.","volume":"18","author":"Fekadu","year":"2018","journal-title":"BMC Psychiatry"},{"key":"R25-20260910","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt.2350","article-title":"An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine.","volume":"110","author":"Whirl-Carrillo","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R26-20260910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v064.i03","article-title":"Exploring diallelic genetic markers: the HardyWeinberg package.","volume":"64","author":"Graffelman","year":"2015","journal-title":"J Stat Softw"},{"key":"R27-20260910","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1037\/met0000032","article-title":"Varying coefficient meta-analysis methods for odds ratios and risk ratios.","volume":"20","author":"Bonett","year":"2015","journal-title":"Psychol Methods"},{"key":"R28-20260910","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/ijms26020589","article-title":"Exploring the pharmacogenomic map of Croatia: PGx clustering of 522-patient cohort based on UMAP + HDBSCAN algorithm.","volume":"26","author":"Brlek","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R29-20260910","doi-asserted-by":"crossref","first-page":"861","DOI":"10.21105\/joss.00861","article-title":"UMAP: Uniform Manifold Approximation and Projection.","volume":"3","author":"McInnes","year":"2018","journal-title":"J Open Source Softw"},{"key":"R30-20260910","doi-asserted-by":"crossref","first-page":"205","DOI":"10.21105\/joss.00205","article-title":"hdbscan: hierarchical density based clustering.","volume":"2","author":"McInnes","year":"2017","journal-title":"J Open Source Softw"},{"key":"R31-20260910","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"key":"R32-20260910","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41397-019-0067-3","article-title":"Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP.","volume":"20","author":"Wigmore","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"R33-20260910","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.pnpbp.2017.01.011","article-title":"Pharmacogenetics of antidepressant response: a polygenic approach.","volume":"75","author":"Garc\u00eda-Gonz\u00e1lez","year":"2017","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0000000000000621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:00:10Z","timestamp":1789030810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0000000000000621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":31,"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000621","relation":{},"ISSN":["1744-6872","1744-6880"],"issn-type":[{"value":"1744-6872","type":"print"},{"value":"1744-6880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"2026-05-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}